SK Bioscience Secures CDC Technology for Rotavirus Vaccine

SK Bioscience announced a new licensing agreement. The company obtained technology from the U.S. Centers for Disease Control and Prevention. The technology will be used to develop a rotavirus vaccine. The agreement was reported by The Korea Herald. The licensing expands SK Bioscience’s vaccine portfolio. It reflects ongoing collaboration between Korean firms and U.S. health agencies. The move aims to address rotavirus infection worldwide. Future updates will track the vaccine’s development progress.